Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract

Joaquim Bellmunt, Christine Théodore, T. Demkov, +14

Journal of Clinical Oncology

Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)

Stéphane Culine, Pierre Kerbrat, A. Kramar, +11

Annals of Oncology

UrologySurgical OncologyCancer CentersGenitourinary CancerMedicine +6

Medroxyprogesterone, interferon alfa‐2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis

Sylvie Négrier, David Pérol, Alain Ravaud, +6

Cancer

Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma

Laurence Albigès, Stéphane Oudard, Sylvie Négrier, +13

Journal of Clinical Oncology

Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial

Nicholas D. James, Armelle Caty, Michael Borre, +5

European Urology

UrologyOncologyHealth SciencesPain MedicineMedicine +8

Treatment of Patients With Metastatic Renal Carcinoma With a Combination of Subcutaneous Interleukin-2 and Interferon Alfa With or Without Fluorouracil

Sylvie Négrier, Armelle Caty, Thierry Lesimple, +5

Journal of Clinical Oncology

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration‐resistant prostate cancer and bone metastases who were pain‐free or mildly symptomatic for pain: a double‐blind, placebo‐controlled, randomized Phase II trial

Nicholas D. James, Armelle Caty, Heather Payne, +7

British Journal of Urology

Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP

Stéphane Culine, Andrew Kramar, Christine Théodore, +12

Journal of Clinical Oncology

Cytokines in Metastatic Renal Cell Carcinoma: Is It Useful to Switch to Interleukin-2 or Interferon After Failure of a First Treatment?

Bernard Escudier, Christine Chevreau, Christine Lasset, +9

Journal of Clinical Oncology

Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial

Sylvie Négrier, David Pérol, Alain Ravaud, +7

Journal of Clinical Oncology

Percy Quattro TrialImmunodeficienciesImmunologyPharmacotherapyImmunotherapeutics +19